SCHEMBL4692525

SCHEMBL4692525

CCCNC(=O)COCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.47
NAMPT P43490 2/20 0.44
FAAH O00519 1/20 0.44
HTT P42858 1/20 0.43
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 3/20 0.41
SPR P35270 1/20 0.41
HPGD P15428 2/20 0.41
MMP1 P03956 1/20 0.40
MMP2 P08253 1/20 0.40
MMP3 P08254 1/20 0.40
MMP9 P14780 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX1 P07099 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24838561 0.90 ALDH1A1 (0.45) MCL1NAMPTFAAHHTTHSD17B10
SCHEMBL18319243 0.88 ALDH1A1 (0.44) MCL1NAMPTFAAHHTTHSD17B10
SCHEMBL13296412 0.87 FAAH (0.55) NAMPTFAAHTSHRALDH1A1HPGD
SCHEMBL23471072 0.85 FAAH (0.62) NAMPTFAAHTSHRALDH1A1MEN1
SCHEMBL14307931 0.84 RAB9A (0.44) NAMPTFAAHHSD17B10ALDH1A1SPR
SCHEMBL23677003 0.84 ALDH1A1 (0.47) NAMPTFAAHHSD17B10TSHRALDH1A1
SCHEMBL13480663 0.84 MCL1 (0.45) MCL1FAAHHTTHSD17B10TSHR
SCHEMBL26227327 0.84 MCL1 (0.45) MCL1FAAHHTTHSD17B10TSHR
SCHEMBL23713358 0.84 FAAH (0.66) NAMPTFAAHMEN1KMT2AEPHX1
SCHEMBL19634653 0.84 FAAH (0.66) NAMPTFAAHMEN1KMT2AEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3831841-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T Global Inc. (US) 2021-06-09 EP disclosed
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-12-22 US disclosed
EP-1496838-A4 SUBSTITUTED AMIDES MERCK & CO INC (US) 2008-07-02 EP disclosed
EP-1496838-A2 SUBSTITUTED AMIDES Merck & Co., Inc. (US) 2005-01-19 EP disclosed
WO-2003077847-A2 SUBSTITUTED AMIDES MERCK & CO., INC. (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368930-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER KRAS, HRAS, NRAS MCL1 172/4885NAMPT 2751/4885FAAH 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.